

RespireRx Pharmaceuticals Inc.  
Form 8-K  
January 05, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 29, 2017**

**RESPIRERX PHARMACEUTICALS INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>1-16467</b>	<b>33-0303583</b>
<b>(State or other jurisdiction of incorporation)</b>	<b>(Commission File Number)</b>	<b>(I.R.S Employer Identification No.)</b>

**126 Valley Road, Suite C**

**07452**

**Glen Rock, New Jersey**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (201) 444-4947**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 29, 2017, RespireRx Pharmaceuticals Inc. (the “Company”) entered into a Common Stock and Warrant Purchase Agreement for \$95,000, which was the last closing under its private placement of up to \$1.15 million (the “Private Placement”) that commenced with an initial closing for \$75,000 on August 29, 2017 and expired on its terms on December 30, 2017. The Company filed a Current Report on Form 8-K in connection with the initial closing on August 30, 2017. In connection with the Private Placement, the Company entered into Common Stock and Warrant Purchase Agreements (each a “Purchase Agreement”) with accredited investors (each, a “Purchaser” and collectively, the “Purchasers”), pursuant to which, the Company sold units for aggregate cash consideration of \$404,500 (including \$75,000 in the initial closing), with each unit consisting of (i) one share of the Company’s Common Stock, par value \$0.001 per share (“Common Stock”), and (ii) one Warrant to purchase an additional share of Common Stock (each a “Warrant” and collectively, the “Warrants”).

The number of Shares and Warrants that have been sold in the Private Placement since its inception are shown in the chart below.

Closing Date	Number of Shares Issued	Number of Shares Issuable Upon Exercise of Warrants
August 29, 2017	75,000	75,000
September 27, 2017	50,000	50,000
September 28, 2017	1,000	1,000
October 5, 2017	6,000	6,000
October 25, 2017	25,000	25,000
November 29, 2017	100,000	100,000
December 13, 2017	20,000	20,000
December 21, 2017	25,000	25,000
December 22, 2017	7,500	7,500
December 29, 2017	95,000	95,000
Total	404,500	404,500

The price per unit in the each closing under the Private Placement was \$1.00 (the “Per Unit Price”). The Warrants are exercisable until 5:00 p.m. on September 29, 2022 and may be exercised at 110% of the Per Unit Price, or \$1.10 per share of Common Stock. The Warrants have a cashless exercise provision and certain “blocker” provisions limiting the percentage of shares of Common Stock of the Company that the purchaser can hold upon exercise. The Warrants are also subject to a call by the Company at \$0.001 per share upon ten (10) days written notice if the Company’s Common

Edgar Filing: RespireRx Pharmaceuticals Inc. - Form 8-K

Stock closes at 250% or more of the Per Unit Price for any five (5) consecutive trading days. The Purchasers were non-affiliated investors. In total, 404,500 shares of Common Stock were purchased for cash in the closings under the Private Placement, together with Warrants to purchase an additional 404,500 shares of Common Stock.

Of the maximum amount available in the Private Placement, up to \$642,000 of units were available be obtained by stockholders who had purchased units in previous unit offerings in December 2016 and March 2017 pursuant to which they had received the right to exchange into subsequent offerings, similar to the rights granted in this Private Placement that are described below. As of December 30, 2017, all of those shareholders had exercised their exchange rights. The Company did not receive any proceeds with respect to units issued upon the exercise of these rights. As of December 30, 2017, 371,716 incremental new shares were issued in connection with the exercise of such rights. In addition, 270,284 warrants originally purchased in the prior unit offerings in December 2016 and March 2017 were cancelled and 642,000 new warrants were issued in connection with these exchanges. The new warrants are substantially similar to the cancelled warrants.

In addition, as set forth in the Purchase Agreement, each Purchaser had an unlimited number of exchange rights, which were options and not obligations, to exchange such Purchaser's entire investment (but not less than the entire investment) into one or more subsequent equity financings (consisting solely of convertible preferred stock or common stock or units containing preferred stock or common stock and warrants exercisable only into preferred stock or common stock) that would be considered as "permanent equity" under United States Generally Accepted Accounting Principles and the rules and regulations of the United States Securities and Exchange Commission, and therefore classified as stockholders' equity, and excluding any form of debt or convertible debt (each such financing a "Subsequent Equity Financing"). These exchange rights were effective until the earlier of: (i) the completion of any number of Subsequent Equity Financings that aggregate at least \$15 million of gross proceeds, or (ii) December 30, 2017. Accordingly, as of the termination of the Private Placement, these exchange rights have also terminated.

In the case of an Acquisition (as defined in the Purchase Agreement) in which the Company is not the surviving entity, the holder of each Warrant would receive from any surviving entity or successor to the Company, in exchange for such Warrant, a new warrant from the surviving entity or successor to the Company, substantially in the form of the existing Warrant and with an exercise price adjusted to reflect the nearest equivalent exercise price of common stock (or other applicable equity interest) of the surviving entity that would reflect the economic value of the Warrant, but in the surviving entity.

Unlimited piggy-back registration rights have been granted with respect to the Common Stock, and the Common Stock underlying the Warrants, unless such Common Stock is eligible to be sold without volume limits under an exemption from registration under any rule or regulation of the SEC that permits the holder to sell securities of the Company to the public without registration.

The shares of Common Stock and Warrants were offered and sold without registration under the Securities Act of 1933, as amended (the "Securities Act") in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. None of the shares of Common Stock issued as part of the units, the Warrants, the Common Stock issuable upon exercise of the Warrants or any warrants issued to a qualified referral source have been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

This description of the Purchase Agreement, including the form of Warrant, does not purport to be complete and is qualified in its entirety by reference to the form of Purchase Agreement (including (i) the schedules thereto, and (ii) the Form of Warrant attached as Exhibit A thereto), which is included as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

### **Item 3.02 Unregistered Sales of Equity Securities.**

The information provided in response to Item 1.01 of this report is incorporated by reference into this Item 3.02. Each Purchaser of shares of Common Stock and Warrants sold in the Private Placement made representations to the Company that such Purchaser met the accredited investor definition of Rule 501 of the Securities Act, and the Company relied on such representations. The offer and sale of the shares of Common Stock and Warrants in the Private Placement were made in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. The offering of the shares of Common Stock and Warrants in the Private Placement was not conducted in connection with a public offering, and no public solicitation or advertisement was made or relied upon by any investor in connection with the offering. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

A list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

### *Cautionary Statement Regarding Forward-Looking Statements*

This report contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. In some cases, forward-looking statements may be identified by words including “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” and similar expressions include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s proposed products, and (iv) the need for, and availability of, additional financing.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic and competitive conditions, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, actual results may differ materially from those set forth in the forward-looking statements. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the Company’s objectives or plans will be achieved.

Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, including the section entitled “Item 1A. Risk Factors” as well in conjunction with the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2017. The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 5, 2018 RESPIRERX PHARMACEUTICALS INC.  
(Registrant)

By: */s/ Jeff E. Margolis*  
Jeff E. Margolis  
Vice President, Treasurer and Secretary

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
10.1	<u>Form of Purchase Agreement (including the Form of Warrant) incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed August 30, 2017.</u>

